# Evaluation of Safety and Efficacy of ProHance in Pediatric Patients <2yrs

> **NCT03750188** · — · COMPLETED · sponsor: **Bracco Diagnostics, Inc** · enrollment: 125 (actual)

## Conditions studied

- Central Nervous System Diseases
- Central Nervous System Neoplasms

## Interventions

- **DRUG:** ProHance

## Key facts

- **NCT ID:** NCT03750188
- **Lead sponsor:** Bracco Diagnostics, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-01
- **Primary completion:** 2019-09-17
- **Final completion:** 2019-10-16
- **Target enrollment:** 125 (ACTUAL)
- **Last updated:** 2020-01-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03750188

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03750188, "Evaluation of Safety and Efficacy of ProHance in Pediatric Patients <2yrs". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03750188. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*